#InvictaDiagnostic #SMEIPO #PCDiagnostics #DiagnosticServices #NSEEMERGE #MumbaiMMR #IPONews
Mumbai: – Invicta Diagnostic, a Mumbai-based provider of pathology and radiology testing services, is set to launch its maiden public offering on the SME segment. The IPO will open for subscription on December 1, with the price band fixed at ₹80-85 per share.
Operating under the brand PC Diagnostics within the Mumbai Metropolitan Region (MMR), the company aims to raise ₹28.12 crore by issuing 33.08 lakh shares at the upper price band. The issue is an entirely fresh issue, meaning all proceeds will go to the company, with no Offer-for-Sale (OFS) component.
🗓️ IPO Schedule and Allocation
The Invicta Diagnostic IPO is part of a series of seven SME public issues opening next week.
| Event | Date |
| Anchor Book Opening | November 28 |
| Public Subscription Period | December 1 – December 3 |
| Allotment Finalization | December 4 |
| Listing on NSE Emerge | December 8 |
The IPO allocation is structured as follows:
-
Qualified Institutional Buyers (QIBs): 50%
-
Non-Institutional Investors (NIIs): 15%
-
Retail Investors: 35%
🏥 Expansion Plans and Market Positioning
Invicta Diagnostic currently operates seven diagnostic centres and one centralised laboratory across the MMR. The core purpose of the IPO is to fund aggressive expansion:
-
₹21.11 crore of the IPO proceeds will be used for the purchase of medical equipment to establish five new diagnostic centres in Maharashtra during FY26 and FY27, employing a hub-and-spoke model.
-
The remainder of the funds will be used for general corporate purposes.
The company is currently valued at ₹107 crore. While operating in the same space as major listed peers like Vijaya Diagnostic Centre (₹10,300 crore m-cap) and Krsnaa Diagnostics (₹2,600 crore m-cap), PC Diagnostics is focusing on localized expansion within Maharashtra.
📈 Financial Performance
Invicta Diagnostic has demonstrated strong growth in its financial performance:
-
Half-Year Performance (Ended Sept 2025): The company reported a profit of ₹4 crore on a revenue of ₹16.95 crore.
-
Full-Year Fiscal 2025:
-
Revenue grew by a robust 90.1% to ₹30 crore, up from ₹15.8 crore in the previous fiscal year.
-
Profit increased by 29.5% to ₹4.9 crore, up from ₹3.8 crore.
-
Socradamus Capital is acting as the merchant banker for the Invicta Diagnostic IPO.
#InvictaDiagnostic #SMEIPO #PCDiagnostics #DiagnosticServices #NSEEMERGE #MumbaiMMR #IPONews
